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PREVENTION AND TREATMENT OF COLORECTAL CANCER WITH 
TURMERIC AND ITS MAIN ACTIVE CONSTITUENT,  
CURCUMIN 
 
ERIN CONNER LUERS
ABSTRACT  
Problem: Colorectal cancer (CRC) is a top three leading cause of death among western 
countries. Epidemiological evidence shows a positive correlation between western diet, 
which consists of high-fat, meat and processed foods. Positive correlations indicate that 
diets high in fruits and vegetables could greatly decrease risk of CRC. Specifically the 
ubiquitous spice, turmeric, and its main active constituent have been broadly researched 
to determine its efficacy in the treatment and prevention of CRC. 
Results: Curcumin proves to be effective in the treatment and prevention of CRC. It acts 
as a chemosensitizer for chemotherapeutics which increases their effectiveness especially 
against chemoresistant CRC cell lines. In many in vitro studies curcumin has inhibited 
critical pathways involved in CRC progression such as Wnt/β-catenin and sonic 
hedgehog pathway. Curcumin can also act as a ligand for VDR, which is significant 
because high vitamin D intake is associated with a decreased risk of CRC.  In vivo, 
curcumin has minimized tumor growth in animal models. In clinical trials curcumin 
proves to be a naturally derived, non-toxic agent.  
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Conclusion: Curcumin and turmeric should be further studied for its use against CRC, 
specifically its use in nanotechnology and NDDS as either a stand-alone nutraceutical or 
a chemosensitizer. Additionally, it would likely be advantageous to prescribe turmeric in 
the diet in combination with black pepper, heat, and oil (which increases its 
bioavailability) in patients at high risk of developing CRC.  
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INTRODUCTION 
Cancer treatment and the discovery of novel therapies and drug delivery 
mechanisms is of high importance, as cancer is the second leading cause of death in the 
U.S., right below heart disease. Effective cancer treatments are generally invasive, 
dangerous, and destructive. According to the American Cancer Society (ACS), colorectal 
cancer (CRC) is the third leading cause of cancer-related death in males and females. The 
ACS also reports that in 2017, 135,430 CRC cases were reported and 50,260 deaths 
occurred due to CRC (“Key Statistics for Colorectal Cancer” n.d.). CRC treatments have 
varied approaches, either localized or systemic: localized treatments consist of surgical 
resection, radiation, and embolization, while systemic treatments consist of 
chemotherapy, targeted therapy, and immunotherapy. Unfortunately, these methods are 
not always effective as the recurrence rate of CRC is very high. Metastatic CRC is 
virtually untreatable and has a 5-year survival chance of about 5% (Wu et al. 2017). 
Putting resources into treatments that minimize the chances of metastasis of CRC would 
greatly reduce the cancer-related deaths.  
Cancer treatment has come a long way over the past few decades. Biotechnology 
has evolved to enhance chemotherapy, radiation therapy, hormone therapy, and targeted 
therapy through the creation or identification of novel drugs and delivery systems for a 
more effective and targeted approach to eliminating cancerous cells and tissues. 
Chemotherapy and radiation are less targeted and therefore attack all cells, including 
healthy cells.  
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In addition to the negative side effects of treatment, cancers are building 
resistance through various pathways. The high rate of recurrence and metastasis in CRC 
can be tied to a small subset of cancer stem cells (CSC) that are resistant to most existing 
therapies (Ramasamy et al. 2015a). The increase of resistance and toxicity associated 
with cancers and existing therapies, as well as heightened aggressiveness of resistant 
cancers after ineffective chemo- and radiation therapy, stimulates interest in using natural 
products to determine their efficacy as chemopreventative agents.  
Polyphenols are secondary plant metabolites with strong antioxidant power and 
other therapeutic benefits; they are generally non-toxic, abundant, and cost effective 
relative to common chemotherapeutics. Many possess a unique molecular structure that 
can interact with multiple carcinogenic pathways, providing them with a multifaceted 
approach to slowing or reversing the progression of cancer (Ramasamy et al., 2015; 
Chang et al., 2008; Sarkar et al., 2010; Pandey and Rizvi, 2009; Gupta et al., 2011; Gupta 
et al., 2013; L. Chen et al., 2006). Curcumin, a natural compound in curcuma longa 
(turmeric) is one such polyphenol that shows potential against many different cancers and 
diseases, but most notably CRC (Bisht et al., 2007; Ramasamy et al., 2015; Gupta et al., 
2011; Gera et al., 2017; Mukherjee et al., 2014; Hong et al., 2006; Ghosh er al.,  2015).  
Specific Aims   
This thesis will explore the use of turmeric and its main active constituent, 
curcumin, in the treatment and prevention of CRC. First, the general use of turmeric and 
curcumin to treat various diseases will be assessed to illustrate their potential as 
therapeutic agents. This thesis will also delve into the pathways involved in the 
 3 
 
pathogenesis of colorectal neoplasia and summarize the published research that displays 
evidence to support the claim that curcumin and turmeric can have anti-carcinogenic 
effects against CRC. Evidentiary support will be accomplished through the use of 
research studies and clinical trials that show the benefits as well as possible adversities of 
turmeric and curcumin. Additionally, a discussion of novel methods of formulation and 
delivery will be explored. 
The goal of this research will be to inform patients and physicians of studies that 
lean towards a natural, plant-based compound that can be recommended for added use in 
specifically western diets, as it is already ubiquitous throughout Southeast Asia and other 
parts of the world. Furthermore, by formulating drugs that utilize curcumin’s benefits 
either as a stand-alone treatment or in combination with existing chemotherapies, 
resistant colorectal cancer cells might be better targeted and effectively killed so as to 
decrease CRC recurrence.  
Due to evolving cancer resistance, natural products are being explored with great 
interest as they have fewer side-effects than standard chemopreventative compounds and 
a unique ability to sensitize resistant cell lines to chemotherapeutics (Cruz-Correa et al., 
2006; Pandey and Rizvi, 2009; Ramasamy et al., 2015; Gupta et al., 2011). Plant-derived 
polyphenols are notable natural compounds that have proven their efficacy against a 
variety of diseases, including cancer. Polyphenols are secondary plant metabolites that 
can serve as a line of defense against ultraviolet radiation and pathogens (Pandey and 
Rizvi, 2009). Long term consumption of these plant derivatives have been associated 
with a reduced risk of cancers, cardiovascular diseases, diabetes, osteoporosis, and 
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neurodegenerative diseases (Pandey and Rizvi, 2009) according to various 
epidemiological studies. Subjects consuming diets rich in fruits and vegetables will have 
a high polyphenol intake.  
Figure 1. Examples of the molecular structure of polyphenol subclasses. Taken from 
(Pandey and Rizvi, 2009). 
 
Figure 1 shows the major subclasses of polyphenols, which include phenolic 
acids, flavonoids, stilbenes, and lignans. Polyphenols commonly highlighted in disease-
fighting research include: (1) resveratrol, a stilbene present in grapes, red wine, and 
bamboo; (2) curcumin, of the curcuminoid subclass, present in turmeric; (3) berberine, 
found in goldenseal and barberry; and (4) EGCG found in green tea (McCubrey et al., 
2017). Resveratrol and berberine are found in low concentrations in food, and it would be 
difficult for an individual to consume enough of these polyphenol through diet alone for a 
significant physiological impact; However, the literature shows that many polyphenols 
 5 
 
can act synergistically and so the combination of various polyphenols in our diet could 
have a more potent cumulative effect (McCubrey et al., 2017; Gupta et al., 2011; Liu et 
al., 2008). Curcumin and EGCG are ubiquitous and therefore easier to incorporate at 
physiologically relevant levels within the diet.  
Polyphenol consumption can vary greatly depending on the food consumed, how 
it is processed, and how it is cooked. Many antioxidants are found in the outer layer and 
skin of foods due to necessity of light for their biosynthesis (Pandey and Rizvi,  2009; 
McCubrey et al., 2017). For example, resveratrol is mostly contained in the skin of 
grapes. Additionally, cooking methods like heating, frying, or boiling all alter polyphenol 
content differently.  
Efficacy of Curcumin as a Broadly Used Nutraceutical 
 
Curcumin is a polyphenol from the curcuminoid subclass, derived from the 
curcuma longa (turmeric) rhizome (root) of the Zingiberaceae (ginger) family. Turmeric 
has been used for centuries in Ayurvedic and Chinese medicine as a comprehensive 
natural remedy and treatment (Gupta et al., 2013; Gupta et al., 2011). Turmeric has been 
well documented as an antioxidant, anti-inflammatory, and antimicrobial agent among 
other uses (Akram et al., 2010). Additionally, it can be used as a natural and non-toxic 
coloring agent due to its bright yellow pigment. Due to turmeric's vast usage as a 
therapeutic for centuries throughout Asia, researchers have been exploring its benefits to 
prevent and fight disease for the last few decades (Pan et al., 1999; Gupta et al., 2013; 
Aggarwal et al., 2013; McCubrey et al., 2017). Turmeric and its active curcuminoid 
constituents, most notably curcumin, have shown great promise in the prevention and 
 6 
 
treatment of a broad spectrum of diseases. There is a plethora of evidence showing 
curcumin’s anti-carcinogenic effects on colorectal cancer (Villegas et al., 2008; 
Ramasamy et al., 2015; McCubrey et al., 2017; Bisht et al., 2007; Chang et al., 2008). 
Turmeric contains many potentially therapeutic compounds other than curcumin and by 
isolating curcumin other constituents of turmeric that have therapeutic potential may be 
eliminated. However, because the majority of research on this topic targets curcumin as 
the compound of interest, this thesis focuses almost entirely on curcumin’s efficacy in the 
treatment and prevention of CRC.  
 
Figure 2. Antioxidant mechanism of curcumin (Ghosh et al.,  2015). 
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Polyphenols are antioxidants that can produce a range of physiological responses 
within the body. Turmeric and curcumin exhibit similar antioxidant effects (see Figure 2) 
as Vitamins C and E. There was some discrepancy in the literature as to whether 
curcumin is part of the flavonoid subclass of polyphenols or only specifically 
curcuminoids (Akram et al., 2010; Gupta et al., 2013; Gupta et al., 2011). Some sources 
reference it as a flavonoid (Akram et al., 2010); However, structurally it does not have 
the characteristic adjacent aromatic rings that most flavonoids have (see Figures 2 and 3). 
Curcumin might have been reclassified into a separate subfamily, curcuminoids, because 
of structural differences.   
As shown in Figure 3, curcumin is a unique compound in that its molecular 
structure has multiple functional groups that can assist in its wide variety of biochemical 
reactions. Curcumin can exist in either the keto (two carbonyl groups on a conjugated 
carbon chain) or enol (one carbonyl and one hydroxyl on conjugated carbon chain) form. 
Curcumin is a -diketone moiety that undergoes keto-enol tautomerism, which can be 
beneficial for curcumin's ability to bind to various signaling molecules, protein carriers, 
as well as RNA and DNA (Gupta et al., 2011). The enol form is the most energetically 
stable and gives curcumin multiple functions: (1) donate and accept electrons for 
hydrogen bonding; (2) chelating agent of metals with a positive charge; and (3) Michael 
acceptor to nucleophilic attack for covalent bonding (Gupta et al., 2011).  
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Figure 3. Molecular structure of curcumin highlighting its functional groups that give 
curcumin its pleiotropic effects. Taken from (Gera et al., 2017). 
 
Gupta et al. demonstrates how curcumin achieves its bioactivity and regulatory 
effects on signaling pathways through its various functional groups and bonding 
formations through covalent, non-covalent hydrophobic, and hydrogen bonding (Gupta et 
al., 2011). Figure 4 shows the dozens of molecules that curcumin has the potential to 
inhibit, mostly through docking studies, which clearly displays its incredible potential as 
a therapeutic. Curcumin can interact with inflammatory molecules, enzymes, protein 
kinases and reductases, metals, carrier proteins, DNA, and RNA (Gupta et al., 2011). The 
phenol rings and carbonyl(s) can interact with macromolecules through hydrogen 
bonding; Through this hydrogen bonding, curcumin can bind to minor groove of AT rich 
regions of DNA (Gupta et al., 2011).   
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Figure 4. Signaling molecules and intermediates regulated by curcumin. Taken from 
(Gupta et al., 2011). 
 
Curcumin as an Anti-Inflammatory and Chemopreventative Agent 
Diabetes mellitus (DM) affects a substantial portion of the world and especially 
those in western countries consuming a high fat diet. Literature indicates that DM 
pathogenesis involves oxidative stress and inflammation and as this thesis discusses, 
curcumin and turmeric reduce oxidative stress and are anti-inflammatory. Curcumin has a 
hypoglycemic effect, which is helpful for diabetic patients for blood sugar maintenance 
(Demmers et al., 2017; Ghosh et al., 2015). In an analysis of randomized controlled trials, 
Demmers et al. found that curcumin intervention showed statistical significance in 
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reducing fasting plasma glucose values with two-hour oral glucose tolerance testing 
(OGTT) and without OGTT, decreasing glycosylated hemoglobin (HBA1c), and 
increasing insulin sensitivity (Demmers et al., 2017); this evidence supports curcumin as 
an anti-diabetic as it improved impaired glucose tolerance. The main study in this review 
assessed curcumin’s efficacy in prediabetic patients and the results showed that 16.5% of 
the control group ended up being diagnosed with type 2 diabetes mellitus (T2DM), while 
none of the curcumin treated group had T2DM after 9 months of treatment 
(Chuengsamarn et al., 2012). Additionally, in T2DM rat models, curcumin significantly 
reduced fasting blood glucose (FBG), blood glucose levels, AUCs of glucose, as well as 
an increased sensitivity to insulin (Su et al., 2017). This study also found that curcumin 
significantly decreased expression of LDL-C receptors, free fatty acid (FFA), and TNF-⍺ 
(cytokine associated with T2DM insulin resistance) serum levels (Su et al., 2017). 
Curcumin also has an inhibitory effect on glycogen synthase kinase (GSK)-3b,  and ALR 
2 which have both been implicated in the development of diabetes (Gupta et al., 2011).  
Furthermore, curcumin also has the potential to be a non-toxic analgesic likely 
due to its anti-inflammatory properties, not unlike the actions of non-steroidal anti-
inflammatory drugs (NSAID). Curcumin was used in a randomized, double-blind trial for 
laproscopic cholecystectomy (LC) patients to determine its efficacy in pain relief 
(Agarwal et al., 2011). 50 LC patients were divided into curcumin and placebo groups 
after LC surgery due to turmeric's known use in India for trauma patients. Patients 
reported their pain/fatigue/adverse events in a journal using a 100-point visual analog 
scale (VAS) for pain as well as a 10-point interval rating scale (IRS) for fatigue. After 3 
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days (D3), there was no statistically significant differences logged for pain or fatigue; 
however, for weeks 1 and 2 (W1 and W2), there was a statistically significant reduction 
of pain in the curcumin-dosed group: 15 +/- 5 compared to the 30+/-13 on the VAS scale 
in the placebo group (Agarwal et al., 2011). This study supports curcumin as a pain 
modulator and could possibly be used for post-operative patients. Although the modes of 
action are not totally clear, pain is associated with inflammation. NSAIDs, though 
effective, come with unwanted side effects. The use of curcumin either in combination 
with these drugs or alone, could help decrease the doses required and therefore the 
negative side effects as studies show that curcumin is well-tolerated in humans.  
Curcumin has the ability to inhibit various intermediaries in the inflammation 
pathways including pro-inflammatory molecules such as lipoxygenase (LOX), TNF-⍺, 
COX-1 and -2, AGP, and MD-2 (Gupta et al., 2011). LOX enzymes are found to 
contribute to various carcinogenic pathways due to their involvement in inflammation 
through the production of eicosanoids (Gupta et al., 2011). Through molecular docking 
trials, curcumin bound to TNF-⍺ via non-covalent bonds at the receptor-binding sites. 
TNF-⍺ is produced mostly by macrophages during immune response and is associated 
with diseases such as inflammatory bowel disease (IBD) and diabetes (Gupta et al., 
2011). Molecular docking studies showed that curcumin directly binds COX enzymes via 
hydrogen bonding through its methyl group (Gupta et al., 2011). COX enzymes are 
involved in the production of inflammatory prostaglandins. The ability for curcumin to 
bind to pro-inflammatory compounds down-regulates their activity which is clinically 
relevant because excess or chronic inflammation is associated with increased 
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tumorigenesis. Meira et al. used multiple treatments of dextran sulfate sodium (DSS) in 
mouse models to simulate episodic colitis to mimic ulcerative colitis (UC) and chronic 
bowel inflammation (Meira et al., 2008). As shown in Figure 5, chronic inflammation 
induces DNA damage through reactive oxygen and nitrogen species (RONS) and 
inflammatory cytokines, which ultimately contribute to tumorigenesis (Meira et al., 
2008).  
 
Figure 5. Inflammation as a tumorigenic trigger. Taken from (Meira et al., 2008) 
Additionally, turmeric serves as an anti-inflammatory by decreasing histamine 
production, which is a common inflammatory compound that lengthens the production 
and half-life of cortisol, and improves circulation (Akram et al., 2010). Histamine is a 
pro-inflammatory released from mast cells, while cortisol is an anti-inflammatory and 
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anti-histamine released from adrenal glands that decreases immune response. Curcumin’s 
ability to increase cortisol helps indirectly decrease histamine production.   
Due to curcumin’s ability to interact with many different molecular pathways, it 
has shown significant promise in multiple different cancers. There is a growing body of 
literature that shows curcumin’s chemotherapeutic benefits against breast, bladder, 
ovarian, and prostate cancers (Zhou et al. 2017; Lee et al. 2005; Zhou et al. 2017; Shi et 
al. 2017; Seo et al. 2016; Hong et al. 2006). 
 In vitro, curcumin restores expression of tumor suppressor protein, E-cadherin, as 
well as inhibits nuclear translocation of β-catenin in breast CSCs (bCSC) which inhibits 
bCSC migration and decreases chances of recurrence and metastasis (Mukherjee et al., 
2014). Curcumin inhibited cell proliferation and reduced migration and invasive abilities 
in bladder cancer cell lines T24 and 5637 through inhibition of β-catenin and reversal of 
epithelial-mesenchymal transition (EMT) (Shi et al., 2017). Excess β-catenin and EMT 
are well known to be contributors in the progression of multiple cancers.  
Curcumin can also be an inhibitor of sarco/endoplasmic reticulum Ca2+ ATPase in 
ovarian cancer cells, which means that it can increase cytoplasmic Ca2+ and lead to 
apoptosis; this anti-cancerous effect did not occur in healthy cells (Seo et al., 2016). 
Curcumin was also found to covalently bond to a DNA methytransferase (DNA MT) 
analogue, M.SssI, and inhibit it (Seo et al., 2016). DNA MTs are involved in methylating 
CpG promotor sequences in tumor-suppressor genes, which silences them and eliminates 
or diminishes a cells ability to suppress tumor growth (Seo et al., 2016).  
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Curcumin inhibited invasiveness of prostate cancer cell lines in vivo and in vitro 
through inhibition of Matrix metalloproteinases (MMPs) (Hong et al., 2006). MMPs are 
zinc dependent endopeptidases that break down extracellular matrix (ECM), which is a 
crucial step in the progression of cancer invasion and metastasis. MMP-2 and -9 are often 
overexpressed in cancers and strongly associated in the progression of metastasis as they 
are involved in the degradation of type IV collagen and metastasis of tumor cells (Hong 
et al., 2006). In an in vitro study, and in a dose-dependent manner, curcumin inhibited 
proliferation through induction of apoptosis and reduction of MMP-2 and MMP-9 
secretion and invasiveness of prostate cancer cell line DU-145 (Hong et al., 2006). In an 
in vivo study of mouse models, curcumin showed a significant reduction in tumor growth 
after implantation of DU-145 cells than did the control group. Also, MMP enzymatic 
activity was reduced in the curcumin treatment group (Hong et al., 2006). These results 
combined show that curcumin may be able to inhibit MMP secretion and inhibit 
proliferation in prostate cancer and potentially other cancers through similar mechanisms. 
Along the same lines, curcumin inhibited tumor promotor 12-O-tetradecanoylphorbol 13 
acetate (TPA) induced upregulation of COX-2 and MMP-9 in the breast cancer cell line 
MCF10A (Lee et al., 2005).  
Curcumin's anti-cancer and anti-inflammatory properties, however, are not 
necessarily as effective  as those of turmeric. One study compared the antioxidant effects 
of curcumin compared to Curcuma longa (turmeric) and concluded that turmeric extract 
showed higher antioxidant power in the majority of antioxidant assays, including DPPH-
/ABTS-scavenging as well as peroxidation of DOPC liposome and FRAP assays, than 
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did isolated curcumin (Račková et al., 2009). This is likely due to the over 200 other 
compounds found in turmeric that can either enhance curcumin's activity in a synergistic 
manner, or work independently to provide their own benefits. Aggarwal et al. highlights 
certain curcumin-independent benefits of turmeric indicating turmeric has more 
therapeutic potential even without the bioactivity of curcumin (Aggarwal et al., 2013). 
This will be discussed further in a later section discussing the potential problems 
associated with curcumin’s therapeutic efficacy. Liu et al. indicates that, generally 
speaking, antioxidant scavenging capacity and synergistic effects are increased when 
combined with other antioxidants in specific concentrations (Liu et al., 2008). This could 
be applied to curcumin’s antioxidant capacity as well. 
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COLORECTAL CANCER PATHOGENESIS 
CRC has a high morbidity and mortality rate in the western world. Generally, it 
has a slow progression and is often detected clinically at a late stage; however, with the 
increase in colonoscopies, clinicians are identifying CRC at earlier stages, which 
increases survival chances. Carcinogenesis occurs in three stages: (1) Initiation, in which 
normal cells obtain mutations/damage and become transformed or initiated cells; (2) 
Promotion, an irreversible process in which abnormal/initiated cells divide with 
mutations and become pre-neoplastic; and (3) Progression, in which pre-neoplastic cells 
become neoplastic and invasive which leads to malignancy and later metastasis (Villegas 
et al., 2008).  
There are two main pathways that contribute to the development of the first stages 
of CRC, the pre-malignant colorectal polyps: (1) adenomatous polyposis coli (APC), also 
known as LOH, or MSS (microsatellite stable) pathway and (2) the serrated pathway 
(Michael O'Brien, MD, Pathology lecture 4/20/17) . Additional pathways are implicated 
in CRC progression from these pre-malignant polyps, often due to their involvement in 
regulation of colorectal cancer stem cells (CSC): (3) the Wnt/β Catenin pathway and (4) 
the hedgehog pathway have been tied to CRC pathogenesis (Schneikert and Behrens, 
2007; Sarkar et al., 2010; Wu et al., 2017; Bahrami et al., 2017). Some contrary evidence 
exists regarding whether or not pathways (3) and (4) are involved in CRC carcinogenesis, 
which will be touched upon (Wu et al., 2017) . Note that other signaling pathways can 
contribute to CRC and this thesis will discuss those that are potentially targeted by 
curcumin. 
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CRC starts as an adenoma or polyp in the mucosa of the colon or rectum, this is 
defined as a pre-invasive neoplasm and people over the age of 50 are at higher risk. This 
stage is non-malignant, and though many people will develop these polyps, only a small 
percentage will progress to malignant tumors; about 5% in men and <5% in women. The 
APC and Serrated pathways both start with a mutation in the stem cells located in the 
mucosal crypts of the colorectum. The APC pathway, also known as the classic pathway 
as it was first discovered over 100 years ago, is responsible for 60-80% of colorectal 
adenocarcinomas while the more recently discovered Serrated pathway, is responsible for 
20-30% of colorectal adenocarcinomas (Summarized from Michael O'Brien, MD, 
Pathology lecture 4/20/17).  
Figure 6. Various stages of CRC progression. Taken from (“Bowel Cancer Staging - 
Size, Position & Spread” n.d.) on 1/24/18. 
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CRC occurrence can be sporadic, in which mutations and carcinogenic events are 
spontaneous, or familial, in which mutations are inherited. Common familial CRCs 
include familial adenomatous polypsis (FAP) and hereditary nonpolypsis colorectal 
cancer (HNPCC). Additionally, inflammation and inflammatory diseases such as 
inflammatory bowl disease (IBD), ulcerative colitis, and Crohn’s disease are associated 
with an increased risk of CRC (Villegas et al., 2008). Figure 6 shows the different stages 
of CRC from polyp formation, to hyperproliferation and progression to an invasive 
neoplastic lesion that can result in metastasis.  
APC Pathway1 
The APC pathway for CRC usually is triggered by a bi-allelic mutation in the 
APC gene of stem cells found in colonic mucosal crypts. This mutation produces a 
truncated APC protein, which loses its function to sequester β-catenin, a protein involved 
in cell-to-cell adhesion and one that acts as a growth promoting nuclear transcription 
factor (Jaiswal et al., 2002). These mutated cells then divide along the crypt’s basement 
membrane but with a loss of growth control and proper maturation capabilities. APC 
pathway is dysplastic, meaning that there is abnormal and disordered cell/tissue growth.  
Stages of APC driven CRC: 
1. Aberrant Crypt Focus/Microadenoma: confined to one or a small number of crypts, 
adenomatous phenotype (i.e. shows low-grade dysplasia).   
2. Tubular Adenoma - small dysplastic polyp, generally with increased expression of 
COX-2 enzyme, which inhibits apoptosis of the cancerous cell. Additionally, there can be 
a mutation in the KRAS oncogene.  
3. High Grade Dysplasia - usually the transition from a low-grade to high-grade 
dysplasia is due to a mutation in the tumor suppressor gene, p53. Characteristics of this 
stage include increased nuclear atypia and increased abnormalities in gland architecture.   
                                                      
1 Summarized from Michael O'Brien, MD, Pathology lecture 4/20/17) 
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4. Invasive Carcinoma - MSS, chromosomal instability with chromosomal breaks, 
deletions, and duplications causes the neoplasm to break through the basement 
membrane.   
 
Serrated Pathway2 
 The serrated pathway for CRC is usually triggered by a mutation in the BRAF 
gene, but KRAF mutations are also notable (Michael O'Brien, MD, Pathology lecture 
4/20/17) . Mutations in either one of these oncogenes disrupts the RAS-RAF-MAP kinase 
signaling pathway, which is involved in cell growth, proliferation, and other mechanisms 
important to malignancies such as cell cycle regulation and angiogenesis (Molina and 
Adjei,2006). The Serrated pathway is hyperplastic, meaning that there is increased cell 
proliferation and cell number. 
Characteristics of Serrated driven CRC: 
1. Cell senescence - phenotypic alteration evident on crypt surface distinct from 
dysplastic aberrant crypts of APC pathway. Effected cells have cytoplasms containing 
small mucin vacuoles if the mutation is in BRAF (microvesicular serrated polyp). In 
contrast, there is less serration and more tufting of the surface with increased large goblet 
cells if KRAF mutation (goblet cell serrated polyp). 
2. BRAF mutatated hyperplastic polyps can become atypical, and referred to as Sessile 
Serrated Adenoma (SSA) and develop dysplasia, once this occurs they are known as 
Dysplastic serrated polyps. 
3.BRAF mutated hyperplastic polyps are generally proximally located and show MSI 
(microsateliite instability) or MSS. 
4. CpG-island methylation. 
 
Wnt/B-Catenin Pathway 
Wnt/β-catenin pathway is a potential target for therapy in CRC carcinogenesis. 
There are two pathways involved: one is canonical (β-catenin) and another is non-
canonical (β-catenin independent) (Bahrami et al., 2017; Schneikert et al., 2007). Most 
                                                      
2 Summarized from Michael O'Brien, MD, Pathology lecture 4/20/17 
 20 
 
patients with CRC harbor a mutation in the β-catenin or APC genes. APC mutations are 
of the classic CRC pathway. Deregulation of the Wnt signaling cascade can be a result of 
an APC mutation (Oving et al., 2002) and can lead to cancer progression. In the absence 
of Wnt ligands, β-catenin sits in the cell membrane and interacts with E-cadherin to help 
mediate cellular adhesion. The excess β-catenin that doesn’t remain in the cell membrane 
(i.e. free in cytoplasm) is usually destabilized/destroyed. However, in the presence of 
Wnt ligands, the β-catenin that is usually destroyed or destabilized in cytoplasm starts to 
accumulate. As shown in Figure 7, once this occurs β-catenin translocates to nucleus and 
binds to transcription factors (TCF;LEF-1)(Bahrami et al., 2017) which ultimately 
leads to activation of specific target genes (Sarkar et al., 2010). 
 
Figure 7. Wnt pathway with and without the presence of Wnt ligands. Taken from 
(Oving et al., 2002) 
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Hedgehog Pathway 
The hedgehog pathway (Hg) is another a potential pathway involved in the 
progression of CRC and therefore a potential therapeutic target for CRC (Wu et al., 
2017). The Hg pathway is involved in the embryonic generation and post-embryonic 
regulation of organs and tissues, including the patterning, growth, and differentiation of 
the gastrointestinal tract (Wu et al., 2017). Though some studies have failed to find a 
positive correlation between Hg pathway and CRC development, the majority of studies 
do find Hg involvement (Wu et al., 2017).  
Out of the three known Hg ligand homologues, two have been associated with 
CRC: the stimulatory Sonic hedgehog ligand (Shh), and inhibitory Indian hedgehog 
ligand (Ihh), as they are found in the GI tract (Wu et al., 2017). As shown in Figure 8, in 
the absence of Hh ligands, Ptc inhibits Smo; However, in the presence of Hh ligand, 
patched 1 receptor (PTC1) is activated, which stimulates the release of Smoothened 
(Smo) and in turn release Gli2 transcription factor, which ultimately stimulates the 
transcription of other Gli transcription factors (Wu et al., 2017). Once activated and 
transcribed, these upregulate Ptc and Wnt (Sarkar et al., 2010), which shows one of the 
ways in which Hg and Wnt pathways have cross-talk and can contribute to similar actions 
in cancer progression. 
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Figure 8. Hg pathway with and without presence of Hh ligands. Taken from (Wu et al. 
2017) 
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CURCUMIN AND COLORECTAL CANCER 
Epidemiological evidence shows that there are lower colon cancer rates in India 
and other parts of Asia (Mohandas et al., 1999). Turmeric has been used medicinally in 
Ayurvedic and Chinese medicine as well, which stimulated interest in understanding the 
natural therapeutic effect of turmeric and its biologically active constituents (Gupta et al., 
2011; Gupta et al., 2013; Račková et al., 2009). Research on turmeric and curcumin has 
evolved from in vitro studies to in vivo studies, and is currently being used in clinical 
trials.  
There are multiple points during carcinogenesis where compounds can 
therapeutically regulate these pathways. Figure 9 outlines the different types of anti-
carcinogenic compounds. Blocking agents are compounds that generally inhibit 
carcinogen formation and act as detoxifying or antioxidant agents which mostly impacts 
the first stage of carcinogenesis: initiation. Suppressing agents are compounds that inhibit 
proliferation and differentiation, which are involved in the latter stages of carcinogenesis: 
promotion and progression (“Anticarcinogenic Factors in Plant Foods: A New Class of 
Nutrients? | Nutrition Research Reviews | Cambridge Core” n.d.). Curcumin, as with 
other polyphenols, show pleiotropic benefits and has the potential to regulate 
carcinogenic pathways at multiple levels and by various modes of action. Therefore, it 
can be a blocking and suppressing agent.  
 Oxidative stress is linked to patients with colorectal cancer. In Figure 9, notice 
that antioxidant defense is most significant in the initiation and promotion stages of 
carcinogenesis. In a study comparing CRC patients (36 subjects) against a control of 
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seemingly healthy individuals (40 subjects), the CRC patients displayed significantly 
higher levels of protein carbonyl and advanced oxidation protein products (AOPP) 
(Chang et al., 2008). Additionally, the CRC patients had decreased levels of antioxidative 
enzymes as well as low serum levels of well-known antioxidants like vitamins C and E 
compared to the control (Chang et al., 2008). Curcumin’s antioxidant activity has been 
compared to that of vitamins C and E (Akram et al., 2010) and its addition through diet or 
NDDS could increase/supplement a patient’s antioxidant defense when they have 
suppressed levels of antioxidant compounds.  
 
Figure 9. Points in carcinogenesis at which different chemopreventative agents take 
effect. Taken from anticarcinogenic factors in plant foods (“Anticarcinogenic Factors in 
Plant Foods: A New Class of Nutrients? | Nutrition Research Reviews | Cambridge Core” 
n.d.) 
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Additionally, Helicobacter pylori infections have been associated with an 
increased risk of gastric and colorectal cancers (Gupta et al., 2013). Turmeric has shown 
antimicrobial activity and in one study, it inhibited H.pylori growth (Gupta et al., 2013). 
Another study showed that curcumin also displayed antimicrobial activity against 
histamine-producing bacteria, which can increase inflammation in the gut and trigger 
carcinogenic pathways (Gupta et al., 2013), as discussed in more detail in the 
introduction of this thesis.  
 
Figure 10. Demonstrates the CRC carcinogenic pathways that can be disrupted with the 
use of curcumin.  This image is taken from (Ramasamy et al. 2015b). 
 
Curcumin has demonstrated through in vivo and in vitro studies the ability to 
disrupt specific pathways involved in CRC carcinogenesis. Figure 10 shows the multiple 
stages in the signaling cascades at which curcumin can inhibit the sonic hedgehog (SHH), 
Wnt/β-catenin, Notch, and PI3k/Akt/mTOR pathways.  Curcumin has the ability to 
inhibit these self-renewal signaling pathways through various receptors, downstream 
effectors, and transcriptional activity (Ramasamy et al. 2015b). The next section will 
specifically highlight curcumin’s action against the Hg and Wnt/β-catenin pathways; both 
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of which are associated with cancer invasion and metastasis due to their involvement in 
CSC and EMT formation (Sarkar et al., 2010). 
Curcumin can regulate Wnt/B-catenin and Hedgehog Pathways 
Multiple polyphenols including curcumin, quercetin, resveratrol, and 
epigallocathechin-3-gallate (EGCG) have been reported to suppress the Wnt pathway 
(Sarkar et al., 2010). The Wnt/β-catenin pathway is associated with tumor growth and 
cancer progression. Additionally, β-catenin overexpression is found ubiquitously in 
cancers such as CRC, BrC (breast cancer), and BlC (bladder cancer) (Bahrami et al., 
2017; Mukherjee et al., 2014; Shi et al., 2017); therefore the Wnt/β-catenin pathway is 
implicated as a possible therapeutic target.  
 
Figure 11. Regulatory action of nutraceuticals on Wnt and Hedgehog signaling in cancer. 
Taken from (Wu et al., 2017).   
 27 
 
Wnt signaling pathway influences the homeostasis and healthy proliferation of 
the colorectum, therefore if it is disrupted, proliferation can become uncontrolled (Wu et 
al., 2017). The colorectum undergoes renewal via apoptosis of old cells which shed into 
the lumen to be expelled through feces roughly once a week. Healthy proliferation and 
monitored signaling for this process is important. However, a disruption in the canonical 
pathway can act as a false and unwanted stimulation which causes hyperproliferation of 
cells containing a detrimental mutation (Schneikert and Behrens, 2007). In the absence of 
Wnt ligands, β-catenin levels are controlled via proteosomal degradation monitored by a 
multiprotein destruction complex that contains active binding sites for β-catenin and APC 
tumor suppressor protein (Bahrami et al., 2017).  
Inactivation of the APC tumor suppressor protein through an APC mutation can 
lead to hyperproliferation of colorectal epithelium. APC mutations are found in 80% of 
sporadic colorectal carcinomas and are also found in familial adenomatous polyposis 
(Schneikert and Behrens, 2007). The APC protein is involved in the degradation of b-
catenin, and as shown in Figure 11, APC and β-catenin are associated when this 
degradation is to occur. If the mutation presents with the removal of the c-terminus or 
elimination of SAMP repeats downstream of MCR, then the APC protein will not be 
functional and b-catenin will accumulate (Bahrami et al., 2017). 
When Wnt ligands are present, they bind to frizzled receptors and LRP co-
receptors (Wu et al., 2017). This activation leads to the degradation of axin, which acts as 
a scaffold for the multiprotein destruction complex, without this, the complex cannot 
properly mediate the phosphorylation of β-catenin to act as a signal for proteosomal 
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degradation. Without the degradation of excess b-catenin, it is free to translocate to the 
nucleus where it interacts with TCF/b-catenin transcription factors that lead to 
transcription of Wnt target genes. 
Curcumin reduces cell viability and induces apoptosis in vitro in multiple gastric 
cancer cell lines via suppression of b-catenin and other Wnt/b-catenin signaling 
compounds (Zheng et al., 2017). Curcumin also significantly inhibited xenograft tumor 
growth in vivo in a dose-dependent manner (Zheng et al., 2017). Though these 
experiments were shown in gastric cancer cell lines, the Wnt/b-catenin signaling cascade 
is also overexpressed in CRC cell lines, which shows a common pathway. This study 
indicates a promising use of curcumin as an anti-proliferative and pro-apoptotic agent 
through its regulatory capability of Wnt pathway. In a different study, the use of 
curcumin treatment caused p53- and p21-independent G2/M phase arrest and apoptosis in 
HCT-116, HCT-11, and HCT-116 cells most significantly through degradation of b-
catenin (Jaiswal et al., 2002). 
Though there is more literature demonstrating the association of curcumin with 
the Wnt/b-catenin pathways, curcumin has also shown to inhibit the Hg pathway. The Hg 
pathway is involved in the continuous renewal of intestinal epithelial cells, which is why 
its dysfunction would be hypothesized to contribute to hyperplasia and cancer 
progression (Wu et al., 2017). In medulloblastoma cells, curcumin regulated the Hg 
pathway by decreasing SHH ligand and PTCH1 receptor at the protein level (Sarkar et 
al., 2010). In another study, curcumin downregulated the Patched and Smoothened 
receptors which are primary players in Hg pathway (Lian et al., 2015). These actions 
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would need to be further tested in CRC cell lines to see if curcumin can have the same 
regulatory capacity on Hg signaling; However, due to Hg signaling being commonly 
found in CRC cell lines, as well as the cross-talk between the Hg and Wnt/β-catenin 
pathways (see Figure 11), curcumin’s inhibitory action is promising.   
Curcumin Activates Vitamin D Receptor 
 The Vitamin D Receptor (VDR) is expressed in the human gut and has the ability 
to regulate cell growth and differentiation (Klampfer, 2014; Bartik et al., 2010; 
Makishima et al., 2002). It is activated by 1,25D3, the most active form of vitamin D. 
Studies show that increased consumption of Vitamin D can decrease CRC incidence by 
up to 50% and significantly decrease GI tumor growth in animal models (Klampfer, 
2014). 1,25D3 potentially prevents hyper-proliferation by arresting cells in the G1/G0 
cell cycle phase as well as by upregulating tumor suppressor genes like p21 (Bartik et al., 
2010).  
The VDR was recently shown to be a possible bile acid sensor in the gut 
(Makishima et al., 2002). The high-fat western diet, and the resulting secondary bile acid 
build-up that results from this diet, increase CRC risk. As toxic bile acid concentrations 
are increased in the gut, specifically lithocholic acid (LCA), carcinogenic pathways can 
be activated (Makishima et al., 2002; Bartik et al., 2010). LCA can bind VDR and initiate 
some of the same downstream pathways as 1,25D3. For example, LCA and 1,25D3 both 
recruit RXR to form the VDR-RXR heterodimer complex. Once formed, it activates 
target gene expression which can regulate bone and mineral homeostasis, cell growth and 
division, as well as a self-detoxification pathway via transcription of CYP3A (Makishima 
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et al., 2002). Though LCA and other bile acids can induce DNA damage, DNA adducts, 
and impairment of DNA repair enzymes at high concentrations, their action as ligands to 
VDR can provide a self-detoxification pathway that increases expression of CYP3A 
(Makishima et al., 2002). CYP3A diminishes the toxicity of these bile acids, providing 
LCA self-detoxification.  
 
Figure 12. Shows the ability of VDR ligands, 1,25D3 and curcumin to modulate cell 
migration capability in CRC cell line Caco-2. Cell migration was measured over a 24 
hour period (Bartik et al., 2010).  
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Curcumin is another novel, but nutritionally derived, ligand that could bind to the 
VDR, recruit RXR to form the necessary VDR-RXR heterodimer, and initiate 
transcription of target genes in human colon Caco-2 cell lines (Bartik et al., 2010). 
Curcumin’s action as a VDR ligand is one way in which it can decrease CRC progression 
as VDR target genes are associated with increased expression of p21, CYP24, and 
increased migration capability (Bartik et al., 2010). Curcumin had an additional function 
of recruiting a VDR transcriptional coactivator, SRC-1, while SRC-1 was not recruited 
by 1,25D3 and LCA. As seen in Figure 12, curcumin acts similarly to 1,25D3 to 
stimulate colonic cell migration in caco-2 cell line, which is significant in that it shows 
the potential for curcumin to initiate wound healing (Bartik et al., 2010).  
Curcumin as an Antiproliferative and Inhibitor of Tumor Progression 
Milacic et al. hypothesized that based on evidence of polyphenols such as EGCG 
acting as proteosomal chymostripsin-like inhibitors, that curcumin might also function as 
a proteosomal inhibitor (Milacic et al., 2008). First, contributors predicted through 
an in silico model that the two carbonyls of curcumin are susceptible to nucleophilic 
attack by the N-terminal threonine of B5 chymostripsin-like proteasomal subunit (Milacic 
et al., 2008). Through this attack, curcumin can be situated into an inhibitory position. By 
inhibiting the proteasome subunit, ubiquinated proteins accumulate because the cell no 
longer has the capability to degrade them through the proteasome; this accumulation 
induces apoptosis (Milacic et al., 2008). Curcumin carbonyl groups and the proteasomal 
subunit interaction was confirmed in vitro through a proteasome activity assay in which 
various concentrations of curcumin were incubated with rabbit 20S proteasome and then 
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three different proteasomal activities were measured: chymotrypsin-like, trypsin-like, and 
PGPH-like. Chymotrypsin-like activity declined with the most significance, and all 3 
activities reduced with the presence of curcumin (Milacic et al., 2008).   
Once curcumin’s inhibitory effects of the proteasome subunit was confirmed, 
another in vitro study demonstrated curcumin’s inhibitory effects on the 26S proteasome 
subunit of human colon cancer cell lines: HCT-116 and SW480 (Milacic et al., 2008). 
Curcumin proved to have an inhibitory effect in both cell-lines in a dose-dependent 
manner. Additionally, curcumin was compared to a known proteasome inhibitor 
(MC132) activity against HCT-116 with similar inhibitory effects, further confirming that 
it acts as a proteasomal inhibitor (Milacic et al., 2008).   
Subsequently, an in vivo test through the implantation of HCT-116 cells in ICR 
SCID mouse models measured curcumin’s efficacy as a proteasome inhibitor (Milacic et 
al., 2008). Once tumors enlarged in mice, they were randomly placed in a control group 
and group treated with curcumin. The curcumin-treated mice showed a 40% inhibition of 
tumor growth, with the average tumor growing to 959 mm3 relative to the controls 1587 
mm3 (Milacic et al., 2008).  Via analysis of proteins extracted from the tumors, the 
curcumin treatment group showed inhibition of proteasomal chymotrypsin-like activity 
by 55%. This study indicated that curcumin can have a profound effect on inhibiting 
tumor progression via inducing apoptosis through proteasomal inhibition.  
Oxidative stress is associated with the initiation and progression of cancer. When 
there is an imbalance of RONS and antioxidants, there can be resulting lipid, protein, and 
DNA damage (Santos et al., 2013). Due to the strong antioxidant capacity along with no 
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to little toxicity associated with polyphenols, they have the ability to minimize oxidative 
stress that leads to cancer development. Nanoencapsulation of polyphenols can be used to 
increase polyphenol pharmokinetics and bioavailability to be more effective at reducing 
cancer development.  
Additionally, as mentioned earlier , MMP-2 and MMP-9 are highly expressed in 
cancer cells and curcumin is able to inhibit or decrease their secretion in prostate and 
breast cancer cell lines (Lee et al., 2005; Hong et al., 2006). Curcumin also inhibited the 
pro-inflammatory enzymes COX-1 and COX-2. An in vitro study involving colon cancer 
cell line colo 205, showed that curcumin inhibited MMP-2 and COX-2 levels, yet 
promoted MMP-9 and COX-1 levels (Su et al. 2006). Though curcumin has been shown 
to inhibit some of these pro-carcinogenic compounds, it is also promoting some of them, 
which could have negative effects (Su et al., 2006). This evidence is inconsistent and 
shows curcumin could have the ability to both inhibit and promote proliferative activity 
depending on the type of cancer cell lines. Though there is contrary data, curcumin still 
showed to significantly repressive invasive capability of colo 205 cells (Su et al., 2006).  
Prostaglandin E2 (PGE2) is a major pro-inflammatory bioactive lipid that is 
discussed throughout the literature to be strongly associated with GI cancers and is a 
potent tumor promotor, which has been shown in vitro and in animal studies (Nakanishi 
and Rosenberg, 2013). PGE2 has the ability to activate a wide range of biochemical 
pathways mainly due to its ability to act as a ligand for multiple receptors, and most 
notably EP G-protein coupled receptors (GPCR) that are ubiquitously expressed 
throughout the body and overexpressed in CRC (Nakanishi and Rosenberg, 2013). EP 
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receptors activate mechanisms for cell proliferation, apoptosis, and angiogenesis which 
all are critical processes in malignant formation (Nakanishi and Rosenberg, 2013).  
Curcumin has shown in vitro to significantly inhibit PGE2 synthesis in colorectal 
cancer cell lines HT29 (COX-2 overexpression) and SW480 (COX-2 deficiency) as well 
as induce apoptosis at higher rates in the HT29 CRC cell lines (Lev-Ari et al. 2006). 
COX enzymes are necessary for the synthesis of PGE2 from arachidonic acid (Koeberle 
et al., 2009). Though the mechanism is not  known, curcumin has the capability to block 
PGE2 biosynthesis by directly binding and inhibiting the microsomal PGE2 synthase-1 
enzyme that converts PGH2 to PGE2 (Koeberle et al., 2009) .  
Curcumin as a Chemosensitizer 
CRC recurrence is high even with resection and chemo- or radiation therapy due 
to the presence of resistant colorectal cancer stem cells (CSC). CSC differ from normal 
stem cells in that they have a combination of the following: (1) self-renewal capability, 
(2) the ability to differentiate, (3) tumorigenicity, and (4) specific surface biomarkers that 
differ from those of normal CSCs (Ramasamy et al. 2015b). The combination of these 
characteristics makes these rare cells contributing to only 1% of tumor mass very 
effective in stimulating carcinogenesis even after treatment (Ramasamy et al. 2015b). 
Therefore, in the majority of cases, the cancer returns. As shown in Figure 13, curcumin 
has the ability to bypass CSC resistance to chemo- and radiation therapy and target CSCs 
and increase their sensitivity to treatment.  
Using curcumin along with known chemotherapeutics (CT) like 5-fluorouracil 
and oxaliplatin can increase CSCs sensitivity to the chemotherapeutic, and decrease the 
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about of CT required (Ramasamy et al. 2015b). Chemotherapy is toxic and destructive to 
the body, while dozens of studies have shown that curcumin is well-tolerated and non-
toxic (Sharma et al., 2001). By adding curcumin and decreasing a given CT, the amount 
of toxins that the body processes can be decreased.  
 
Figure 13. Proposed mechanism targeting colorectal cancer stem cells (CSC). 
Chemotherapy and radiation alone are found to be ineffective against most cases of 
colorectal cancer due to the existence of resistant colorectal CSC. However, effective 
treatment has been shown in vivo and in vitro when the CSC are targeted with a 
combined therapy of a known chemotherapeutic agent with curcumin as a 
chemosensitizer, making CSC more sensitive to the chemotherapy using a novel delivery 
system such as nanotechnology. Taken from (Ramasamy et al. 2015b). 
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Curcumin has proven to increase sensitivity of chemo-resistant CRC cell lines, 
and specifically those that express CSC properties and markers (Ramasamy et al. 2015b). 
FOLFOX is commonly used when treating CRC, though it can often be ineffective as 
chemoresistant CSC are not effectively eliminated, making recurrence inevitable 
(Ramasamy et al. 2015b). In multiple studies, combination therapy of curcumin with 
FOLFOX has bypassed CSC resistance and increased their sensitivity to this 
chemotherapeutic (Ramasamy et al. 2015a). Curcumin not only improves the efficacy of 
drugs such as the standardly used FOLFOX, but it acts as a chemosensitizer to other 
drugs such as the less common doxorubicin (DOX), daunorubicin (DAUN), and dasatinib 
(Hintzpeter et al., 2015; Nautiyal et al., 2011). 
 DOX and DAUN are anti-tumor anthracycline drugs used in various cancers 
including breast and lung cancer; however, they are generally not used in CRC because 
cell lines display chemoresistance to anthracyclines therefore require higher doses of the 
drug in order to be effective (Sonowal et al. 2017). At high doses, anthracyclines become 
cardiotoxic due to their conversion to the secondary alcohol daunocubinicol by carbonyl 
reductase 1 (CBR1) (Hintzpeter et al. 2015). CBR1 and aldose reductase (AR) inhibitors 
have both proven to increase cell sensitivity to anthracyclines and decrease their 
cardiotoxic effects.  
Hinztpeter el al. confirmed via Western-Blot that A549 cells (lung cancer cell 
line) as well as multiple CRC cell lines (HT-29, Caco-2, SW-480) displayed basal 
expression of CBR1, indicating their ability to convert anthryacyclines to cardiotoxic 
compounds (Hintzpeter et al., 2015). Curcumin was shown to be a tight-binding inhibitor 
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of CBR1 in A549 cell line (lung cancer cell line) causing a significantly lower reduction 
of DAUN to its cardiotoxic metabolite (Hintzpeter et al. 2015). Due to the presence of 
CBR1 in multiple CRC cell lines, there is a strong possibility that curcumin would show 
similar results in CRC. Therefore, combination therapy of curcumin and anthracyclines 
could decrease cardiotoxic risk associated with using anthracyclines for CRC treatment.  
 Aldose reductase (AR) inhibitors, such as fidarestat, also showed potential to 
increase CRC sensitivity to anthracyclines with decreased cardiotoxic side effects. In 
mice xenografts, fiderastat demonstrated an ability to increased DOX-induced death of 
HT-29 and SW480 cells (Sonowal et al., 2017). Interestingly, curcumin displayed an 
inhibitory effect in vitro on aldose reductase (ALR2) in human erythrocytes (Muthenna et 
al., 2009)..  
Dasatinib is an Src inhibitor used as a CT against CRC that also has limited 
effectiveness  with chemo-resistant cell lines such as HCT-116 and HT-29 that display 
CSC markers (Nautiyal et al., 2011). The overexpression of Src in colorectal cancer is 
associated with accelerated metastasis and increased chance of developing drug 
resistance (Chen et al., 2014). Combination treatment of curcumin and dasatinib was 
shown to reduce CSC biomarkers: ALDH, CD44, C133, CD166 (Nautiyal et al., 2011) 
Though curcumin is a chemosensitizer for the above reported drugs, it potentially 
negates the effects of other chemotherapeutics. One study reported that curcumin 
aggravated cancer risk when combined with etoposide, which is often used to treat lung 
and breast cancers (Moos et al., 2004).  
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Curcumin can also target resistant colorectal CSC through inhibiting survival 
proteins. Resistance in cancer is partly due to existence of survival proteins including 
Bcl-2, which curcumin has been shown to inhibit through docking studies via one 
particular cavity of Blc-2 (Gupta et al., 2011). Bcl-2 is upregulated in many cancers; it is 
an apoptosis regulator that can help cells become resistant by evading apoptosis. Multiple 
studies show that Blc-2 inhibitors increase the chemosensitivity of cancers including 
breast, colorectal, and acute myeloid leukemia (Zhou et al., 2017; Wu et al., 2015; Rao et 
al., 2011). One study showed that combination therapy of mitomycin and curcumin 
significantly reduced blc-2 and blc-w expression in breast cancer stem-like cells (Zhou et 
al., 2017). Additionally, curcumin successfully induced apoptosis through reduced 
expression of blc-2 mRNA and protein in acute myeloid leukemia cell lines; curcumin 
also induced a subsequent loss of MMP in the same study (Rao et al., 2011). The 
combination of decreased blc-2 and loss of MMP both induces apoptosis in these cancer 
cell lines, and decreases chance of invasion as MMPs are critical to the metastatic 
process.  
Clinical Trials 
Overall, clinical trials indicate that curcumin is well-tolerated and non-toxic at 
high doses for CRC patients taken on a daily basis for several months (Sharma et al., 
2001). Curcumin has been shown in vitro to prevent aberrant crypt foci (ACF) and 
adenomas in murine models, which, as discussed in the CRC pathogenesis portion of this 
thesis, is the first stage of the APC pathway (Carroll et al., 2011). Curcumin was used in 
a "Phase IIa Clinical Trial of Curcumin for the Prevention of Colorectal Neoplasia,” 
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which resulted in patients showing a significant (40%) reduction of ACF when treated 
with an oral 4g curcumin dose (Carroll et al., 2011). However, the reduction was not 
found in patients treated with 2g of curcumin orally. Patients over the age of 40 with a 
history of smoking were recruited for the clinical trial to test the efficacy of curcumin on 
PGE2 and 5-HETE levels in ACF and total number of ACF (Carroll et al., 2011). The 
study was completed in two consecutive stages, each consisting of 30 day treatment 
periods. The first stage group participants (20 subjects) were initially dosed of 2g of 
curcumin daily to test toxicity. No signs of toxicity appeared at an oral dose of 2g, 
therefore stage 2 participants (20 subjects) were approved for a dose of 4g of curcumin 
daily (Carroll et al., 2011).   
This study was intended primarily to assess whether or not curcumin decreased 
the production of two eicosinoids, PGE2 and 5-HETE, in ACF. The results were not 
statistically significant on the reduction of the targeted eiconsinoids; however, there was 
a statistically significant reduction in overall ACF in the 4g cohort: 17.8 +/- 2, baseline vs 
11.1 +/- 2.8 postintervention; P<0.005 (Carroll et al., 2011). This study was partially 
based on the idea that smokers had high eiconsinoid levels in bronchial epithelium and 
researchers believed this could be paralleled in the colorectum. It is important to note that 
the suspected inflammatory response via increased levels of PGE2 and 5-Hete were not 
detected in the ACF or normal mucosa of the colorectum of smokers as it appeared in 
bronchial epithelium. Curcumin failed to decrease eicosinoid levels, however another 
study showed similar results with celecoxib, a NSAID, that also failed to reduce this 
inflammatory eiconisoids (Carroll et al., 2011).  
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Contributors concluded that with a daily dose of 4 g curcumin over 30 days, there 
is a significant reduction in ACF. From these results, the potential effects the continued 
use of curcumin can be predicted.. Though curcumin did not significantly decrease PGE2 
and 5-HETE levels, curcumin likely effects other signaling pathways involved in CRC 
progression (Carroll et al., 2011). Alternatively, as mentioned, bioavailability of 
curcumin is low and that could be a contributing factor to the failure of curcumin to lower 
eiconsinoid level in this study. Curcumin and its conjugates could also be absorbed in the 
more proximal sections of the GI tract and have fewer absorption rates in the colorectum. 
Also, this study did not take into account possible effects of using turmeric as a whole 
natural product, rather than just the isolated curcumin constituent.  
Another randomized, controlled clinical trial showed that FAP patients showed 
decreased polyp count when treated with curcumin in combination with quercetin (Cruz-
Correa et al., 2006).This supports the claim that curcumin could be used for preventative 
measures as a supplement for patients at high risk of CRC.  
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POTENTIAL PROBLEMS WITH CURCUMIN 
In opposition to the large body of research indicating curcumin as a 
chemopreventative, Moos et al. reported that, in vitro, curcumin acted analogously to 
compounds that disrupt function of the tumor suppressor gene, p53, in colorectal cancer 
cells (Moos et al., 2004), which implicates curcumin as a possible carcinogenic. This 
study indicated that curcumin inhibited phosphorylation of p53 in RKO wild-type p53 
cells which ultimately inhibited p53-DNA binding that is necessary for transcribing 
important tumor suppressor proteins. Furthermore, curcumin’s α, β-unsaturated ketones 
can react covalently with NF-kβ which eliminates or decreases transactivation (Moos et 
al., 2004). Even though NSAID and β-carotene were both implicated in epidemiological 
studies to decrease colon cancer (NSAID) and tobacco-related cancers (β-carotene), there 
was a discrepancy between the benefits of diet and then the supplementation of a single 
ingredient (Moos et al., 2004), meaning that beneficial outcomes cannot always be 
reduced to a single agent. 
This reasoning is analogous to Dr. Michael Gregor’s theory on the reductionist 
trap, which states that is not always beneficial to isolate a given compound and reduce a 
diet down to a single ingredient; e.g. the benefits of curcumin supplementation are not as 
good as adding turmeric as a whole ingredient to one’s diet (Turmeric or Curcumin: 
Plants vs. Pills | NutritionFacts.org n.d.). With regard to possible carcinogenic effects, it 
should be noted that curcumin might act differently than turmeric. This is where more 
targeted therapy and NDDSs could be useful so as to modify drug delivery to only use 
curcumin where it has proven its efficacy in the lab. 
 42 
 
One study reviewed the efficacy of a multitude of natural products that have 
shown therapeutic promise in the lab. This study suggests that many of the ubiquitously  
studied bioactive compounds, like curcumin, are false positives (Bisson et al., 2016). This 
study is included to show that not all research has given polyphenol activity positive 
results. Mostly this suggests the problems associated with bioavailability and rapid 
metabolism of polyphenols and this does not mean that the polyphenols in their original 
form, or metabolite form cannot be successful clinically, as the majority of the literature 
shows promising data.  
Absorption, Bioavailability, and Rapid Metabolism of Curcumin 
Curcumin is known to have a low bioavailability due to its poor aqueous 
solubility (Wang et al., 2018). This creates some challenges as far as whether or not it can 
be used therapeutically. There is a growing body of research on how to increase turmeric 
and curcumin bioavailability. A large amount (40-85%) of orally consumed curcumin is 
unchanged and excreted in feces, while the remainder is absorbed and metabolized 
mostly through the intestinal mucosa and liver (Akram et al., 2010). The next section of 
this thesis will focus on NDDS for curcumin that address these issues.  
Curcumin is rapidly metabolized in the GI tract. As displayed in Figure 14, 
curcumin has various metabolites. It undergoes conjugation and produces curcumin 
glucuronide and curcumin sulfate, and then is reduced to tetra-, hexa-, and octa-
hydrocurcumin and then hexahydrocurcuminol (Ghosh et al., 2015). This was shown in 
vivo in rat, mouse, and human models. The rapid metabolism of curcumin could be 
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avoided through NDDS, however it is notable that the metabolites could potentially have 
positive physiological and anti-carcinogenic effects.  
 
Figure 14. Metabolism of curcumin. Taken from (Ghosh et al., 2015). 
Use of Turmeric Verses Curcumin 
Though curcumin is a bioactive ingredient in turmeric, there are many other 
ingredients that could either be contributing to increase its activity, or work on their own 
to produce other positive physiological effects. Furthermore, often compounds such as 
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polyphenols are modified in some way throughout the digestive and absorption process 
which means that different variations of the compound could be acting on different 
tissues.   
When considering epidemiological evidence as a major contributing factor of why 
a certain substance is isolated and tested, the form the population actually consumes the 
compound should be considered. Indians and other consumers of turmeric are not taking 
curcumin pills, they are making curries that use turmeric as a whole ingredient and often 
combine it with other substances that increase bioavailability such as black pepper 
(piperine) or heated in oil, a technique called tempering, which provides the fat-soluble 
compound to be more readily absorbed by obtaining a lipid-bound formulation that is 
often emulated in the lab for an increased bioavailability, making it more clinically 
relevant.  
Aggarwal et al. indicated that curcumin-free turmeric displayed anti-inflammatory 
and anti-cancerous activity (Aggarwal et al., 2013). Therefore, curcumin is not the sole 
biologically active compound in turmeric. This study notes that turmeric oil, another 
component of turmeric, increases bioavailability of turmeric’s components. The 
synergistic effect of the turmeric oil leads further implication that the South Asian/Indian 
cooking technique of "tempering" spices with heat and oil before consuming them could 
improve solubility and bioavailability as turmeric is lipid soluble/lipophilic. There are 
studies reviewing the efficacy of lipid-based NDDS with curcumin and other lipid-
soluble compounds which is further discussed in the Novel Drug Delivery Systems 
section of this thesis. For example, THC and CBD, the active constituents of marijuana, 
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are lipophilic and have low bioavailability when orally consumed; however, when 
combined with dietary lipids, their absorption levels increase (Zgair et al., 2016).  
   
  
 46 
 
NOVEL DRUG DELIVERY SYSTEMS 
The emergence of novel drug delivery systems (NDDS) is improving disease 
therapies for a multitude of reasons: (1) it sustains a given concentration and prolongs 
half-life of a compound or drug by protecting it from metabolism, conjugation, and 
absorption into unwanted tissues. All of which occur with conventional delivery methods 
including oral intake and injection; (2) it provides an opportunity to encapsulate a drug 
with a coating containing known biomarkers. This method is useful for targeting specific 
receptors on the targeted cell of the tissue/organ as well as for improvement of a 
compounds bioavailability and absorption rates (Nair et al., 2010; Santos et al., 2013; 
Acosta, 2009). Due to curcumin and other polyphenol’s low bioavailability, NDDS have 
been crucial to making these compounds more promising therapeutic agents in the 
clinical setting.   
There is a growing body of research on the nanoencapsulation of polyphenols, 
including curcumin (Nair et al., 2010; Gera et al., 2017; Acosta, 2009; Santos et al., 2013; 
Wang et al., 2018). When considering nanoparticle formulation there are many important 
factors that determine the encapsulated compound’s bioavailability, half-life, and ability 
to target a specific tissue: (1) size of the particle and surface-to-volume ratio; (2) surface 
charge (positive, negative, or neutral); (3) encapsulant composition (i.e. lipid, protein, 
cholesterol content) (Nair et al., 2010; Gera et al., 2017; Acosta, 2009). Several studies 
showed data that indicated nanoencapsulation of curcumin was effective in increasing 
systemic absorption, or nano-chemopreventative capacity (Nair et al., 2010).  
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Wang et al. demonstrated that curcumin, as a lipophilic compound, displayed a 
lower degradation rate when encapsulated by the plant derived proso millet protein 
(Wang et al., 2018). Millet protein extraction produced highest hydrophobicity when 
extracted with ethanol as opposed to a wet milling method; hydrophobicity (S0) is 
associated with an increased stability and bioavailability (Wang et al. 2018). Millet 
protein's use as an encapsulant was studied because natural food proteins have inherent 
gelation and emulsification characteristics, and they are conveniently biodegradable and 
often non-toxic. Additionally, plant-derived proteins are associated with less adverse 
effects and dietary conflicts with patients than what is seen with animal-derived proteins.   
 
Figure 15. Mechanism of collecting cannabinoids in micelles for increased intestinal 
absorption. Taken from (Zgair et al., 2016). 
 
Kurien et al. performed a study indicating that heating curcumin can have a 12-
fold increase in its water solubility (from 0.6 mg/ml to 7.4 mg/ml) (Kurien et al., 2007).  
Heat extraction has proved to keep the integrity of the compound while increasing its 
bioavailability. As previously mentioned, the traditional cooking method for turmeric and 
curcumin is to temper it in oil with heat before its consumption. The heat and fat 
solubility of turmeric could increase bioavailability although there has not been research 
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focused on this cooking technique and the clinical implications. Mostly research has 
focused on use of curcumin with nanotechnology and other NDDS.  
For comparison of another lipid-soluble compound with low bioavailability, a 
study involving the increased systemic exposure of cannabis when co-administered with 
dietary lipids (see Figure 15) showed a 2.5 to 3-fold increase in systemic absorption 
(Zgair et al., 2016). This study indicates that curcumin could act similarly to 
cannabinoids as it is another lipid-soluble compound that could benefit from co-
administration of dietary or pharmaceutical lipids. One randomized, double-blind study in 
human subjects showed that use of a soy lecithin as a lipophilic matrix increased 
absorption by 19-fold for curcumin, but had a greater plasma appearance when 
formulated with another curcuminoid, demethoxycurcumin (Cuomo et al., 2011). This 
novel lecithin formulation of curcuminoids supports the claim that lipid-based 
formulations of curcumin and other curcuminoids is of sound reasoning and highlights 
the point of using dietary lipids in combination with curcumin and turmeric consumption 
to increase its systemic action. Additionally, it shows that curcumin is not the only 
curcuminoid that can have relevant physiological effects.  
Shoba et al. demonstrated that piperine, a constituent of black pepper, 
demonstrated a synergistic response in combination with curcumin in both animal and 
human subjects with no adverse effects (Shoba et al., 1998). In a rat model, a control 
group was treated with solely curcumin in an oral dose of 2g/kg, while the treatment 
group was given an oral dose of 2g/kg curcumin immediately followed by 20mg/kg of 
piperine. The rats with the combination treatment of curcumin and piperine increased the 
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bioavailability of curcumin by 154% (Shoba et al., 1998). A comparable treatment 
amount was used in human subjects and the dosage was not changed to reflect differences 
in body weight. Because the dose of curcumin and curcumin+piperine were the same as 
the rat model, the relative dose was much smaller per kg for humans. Human subjects 
displayed an astounding 2000% increase in curcumin bioavailability when taken with 
piperine (Shoba et al., 1998). This study illustrates the point that various foods can work 
synergistically to increase bioavailability. Such consideration can be taken into account 
when developing drug strategies, but patients and physicians can also take this 
knowledge and apply it as a preventative measure at home. When consuming turmeric, 
one might also consider adding black pepper and tempering with heat and oil to increase 
absorption rates. These methods are already implemented in traditional cooking 
throughout parts of Asia, and are simply justified in the lab to benefit the pharmokinetics 
and bioavailability of these dietary substances.  
In a randomized, double-blind study with human subjects, different novel and 
standard forms of curcuminoids were orally consumed to test which formulation had the 
best absorption rates (Jäger et al., 2014). The results showed that a novel formulation of 
curcumin, which combined a hydrophilic carrier along with cellulosic derivatives and 
other natural antioxidants increased systemic appearance by 45.9 fold in comparison to 
standard curcumin (Jäger et al., 2014). Additionally, Bitsht et al observed the efficacy of 
nanoencapsulation of curcumin with cross-linked polymers in comparison to free 
curcumin against pancreatic cancer cell lines (Bisht et al., 2007). This study indicated that 
with this NDDS, curcumin has increased cytotoxicity and anti-inflammatory effect 
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through the down-regulation of pro-inflammatory cytokines like IL-6, IL-8, and TNF-⍺ 
(Bisht et al., 2007). These effects were also shown with free curcumin, although in most 
cases nanoencapsulation increased the effectiveness of the nutraceutical.   
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CONCLUSION 
This literature review shows that there is evidence for and against the use of 
curcumin as a chemopreventative agent in human subjects; However, the overwhelming 
body of research indicates curcumin as a strong potential as a chemosensitizer and stand-
alone drug for CRC as well as other cancers and disease. Therefore, curcumin and 
turmeric should still be further researched in clinical trials to better understand its effects 
against the treatment and prevention of CRC. Current clinical trials have shown promise 
for curcumin’s chemopreventative effects, especially in ACF formation, but have lacked 
the strong positive results that have been shown in vitro and in vivo in animal models. 
Most clinical trials emphasize the problems of low bioavailability associated with 
curcumin and other polyphenols, and it will be important for future studies to use NDDS 
like nanoencapsulation and combination therapies to increase polyphenol potency in 
subjects and hopefully be more successful in the clinical setting.  
From here, research on the efficacy of turmeric and curcumin against CRC should 
continue, especially when involving the use of NDDSs and chemosensitizing action. 
NDDS is critical for overcoming the issue of low bioavailability of curcumin, however 
systemic circulation might not be the only method for curcumin to act as a 
chemopreventative agent. There is sound reasoning that the high colonic luminal 
concentration of curcumin and turmeric in the GI tract could greatly contribute to a 
decrease in CRC. This could be through various pathways, but colonic bathing solution 
with curcumin means that there is a high amount of anti-inflammatory and antioxidant 
activity, which is shown to help prevent and treat CRC throughout the literature. 
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Exploring alternate ways to approach cancer treatment is of high demand because 
many treatments, though cancer-fighting, are extremely detrimental and toxic, causing 
almost as much damage as the cancer in the first place. It could be beneficial for 
physicians to incorporate dietary suggestions as a preventative measure, especially in 
patients at high risk of CRC. The long history of turmeric use in Ayurvedic and Chinese 
medicine and diet shows that turmeric has capacity to providing desirable therapeutic 
effects and chemopreventative measures with no toxicity. Notably though, standard 
delivery methods for consuming turmeric and curcumin involve its combination with oils, 
heating techniques, and combination with synergistic spices like pepper/piperine, which 
likely contributes to its bioavailability and chemopreventative effects for regular 
consumers of the spice.  
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